SCHEDULES

C1SCHEDULE 13Tax relief for expenditure on vaccine research etc

Annotations:
Modifications etc. (not altering text)
C1

Sch. 13 modified (with effect as specified in art. 2 of the commencing S.I. of the commencing S.I.) by Finance Act 2004 (c. 12), s. 53(2)(6); S.I. 2004/3268, art. 2

Part 5Supplementary provisions

I127Interpretation

1

In this Schedule—

  • the Inland Revenue” means any officer of the Board;

  • life assurance business” has the meaning given in section 431(2) of the Taxes Act 1988;

  • national insurance contributions” means contributions under Part 1 of the Social Security Contributions and Benefits Act 1992 (c. 4) or Part 1 of the Social Security Contributions and Benefits (Northern Ireland) Act 1992 (c. 7);

  • F1...

  • payment period” has the meaning given in paragraph 17(2) of Schedule 20 to the Finance Act 2000 (c. 17);

  • research and development” has the meaning given by section 837A of the Taxes Act 1988;

  • surrenderable loss” has the meaning given in paragraph 16(2).

2

Section 839 of the Taxes Act 1988 (connected persons) applies for the purposes of this Schedule.

3

For the purposes of this Schedule a company not within the charge to corporation tax that incurs qualifying expenditure is treated as having such accounting periods as it would have—

a

if it carried on a trade consisting of the qualifying R&D activity on which the expenditure is incurred, and

b

if it had started to carry on that trade when it started to carry on that activity.